Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 291-103-1 | CAS number: 90341-71-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- since October 12,1992 to November 13,1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliance with international guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Test was not valid at time of test conduct
- Species:
- guinea pig
- Strain:
- Pirbright-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: HOECHST AG, Kastengrund, SPF breeding colony
- Weight at study initiation: 318 ± 30 g
- Housing: in fully air-conditioned rooms in Makrolon cages (Type 4) on soft wood granulate, in groups of 5 animals
- Diet : Altromin 3112 for guinea pigs and rabbits, ad libitum
- Water : tap water in plastic bottles, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 55 ± 20 %
- Photoperiod: 12 hours daily - Route:
- intradermal and epicutaneous
- Vehicle:
- other: isotonic saline solution and Freud's Complete adjuvant
- Concentration / amount:
- 5% of test substance (Intradermal induction treatment)
25% of the test substance (Dermal induction treatment)
25% of the test substance (Dermal challenge treatment) - Route:
- epicutaneous, occlusive
- Vehicle:
- other: isotonic saline solution and Freud's Complete adjuvant
- Concentration / amount:
- 5% of test substance (Intradermal induction treatment)
25% of the test substance (Dermal induction treatment)
25% of the test substance (Dermal challenge treatment) - No. of animals per dose:
- Determination of primary not irritating concentration: 6
Determination of intradermal tolerability: 3
Sentinel group: 5
Control group: 5
Treatment group: 10 - Details on study design:
- RANGE FINDING TESTS:
Determination of the primary non-irritant concentration:
In a dermal-occlusive test for primary skin irritation, each of the following test concentrations was applied to the left flank of two guinea pigs:
25.0 % TS in isotonic saline
5.0 % TS in isotonic saline
1.0 % TS in isotonic saline
The hair on the left flanks of the animals was removed mechanically. 0.5 mL of the test substance preparation was applied to a 2 x 2 cm cellulose patch, which was then fixed to the left flank and covered occlusively for 24 hours with a bandage and film. 24 hours after removal of the patches, the treated skin areas were examined for erythema and oedema
Determination of the tolerance of intradermal injections:
To determine the tolerance of intradermal injections, each of the following preparations (5.0%, 1.0%, 0.2% in isotonic saline) was administered twice by intradermal injection to 3 guinea pigs. The injection sites (sites 1, 2 and 3) were all within a dorsal area measuring 2 x 4 cm in the vicinity of the shoulder.
MAIN STUDY
A. INTRADERMAL INDUCTION
- No of Injections: 2 x 3 preparations: 50% FCA, 5% TS in 0.9% NaCl, 5% TS in 50% FCA - treatment group
50% FCA, 0.9% NaCl, 50% FCA - control and attending group
- Exposure period: Injection on Day 1, observation Day 1 to Day 7
- Site: shoulder
B. DERMAL INDUCTION EXPOSURE
- No. of exposures: one
- Exposure period: 48 hours
- Test groups: 25% TS in 0.9% NaCl
- Control group: 0.9% NaCl
- Site: shoulder
- Frequency of applications: single
- Duration: Day 8 to Day 22
- Concentrations: 25%
C. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 22 (15 for attending group)
- Exposure period: 24 hours
- Test groups: 25% TS + 0.9% NaCl
- Control group: 25% TS + 0.9% NaCl
- Site: right flank: TS; left flank: 0.9% NaCl
- Concentrations: 25%
- Evaluation (hr after challenge): 24 and 48 hours - Positive control substance(s):
- no
- Positive control substance(s):
- not specified
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 6
- Total no. in group:
- 10
- Clinical observations:
- dry, rough and encrusted skin
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 25%. No with. + reactions: 6.0. Total no. in groups: 10.0. Clinical observations: dry, rough and encrusted skin.
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of the present study, six of ten animals of the treatment group showed a positive skin response after the challenge procedure.
Based on the results of this study Remazol-Brillantblau BB neu may cause sensitisation by skin contact. - Executive summary:
Testing for sensitising properties of Remazol-Brillantblau BB neu was performed in female Guinea pigs according to the method of MAGNUSSON & KLIGMAN. Intradermal induction was performed using 5 % Remazol-Brillantblau BB neu in isotonic saline. Dermal induction and challenge treatment were carried out with 25 % Remazol-Brillantblau BB neu in isotonic saline.
Very slight to moderate erythema and very slight edema as well as dry, rough and encrusted skin were observed in the treatment group 24 and 48 hours after removal of the occlusive bandage. No signs of irritation occurred in the control group. The skin surface of all animals was discolored light blue.
Under the conditions of the present study, six of ten animals of the treatment group showed a positive skin response after the challenge procedure.
Based on the results of this study Remazol-Brillantblau BB neu may cause sensitisation by skin contact.
Reference
The substance is considered to be sensitising if 30 % of the animals in the treated group definitely show a positive reaction.
Challenge treatment:
Very slight to moderate erythema and very slight edema as well as dry, rough and encrusted skin were observed in the treatment group 24 and 48 hours after removal of the occlusive bandage. No signs of irritation occurred in the control group. The skin surface of all animals was discolored light blue.
Clinical signs:
The intradermal injections with Freund's Adjuvant caused severe erythema and edema, indurations and encrustations (evaluation of erythema formation was not possible at the sites treated with the test substance due to intensive blue discolourations). The application sites treated with the test substance showed edema, indurations and encrustations. Evaluation of erythema formation was not possible. Injections of the vehicle alone did not cause any sign of irritation. Due to these strong irritation reactions of the skin, 10% sodium dodecylsulfate was not applied at day 7.
After the removal of the patch at day 10, erythema and edema, scabbed and encrusted skin as well as necrosis and open wounds were observed at the application sites. Additionally the application sites of the treatment group were discoloured light blue.
Assessment
Under the conditions of the present study, six of ten animals of the treatment group showed a positive skin response after the challenge procedure.
Based on the results of this study Remazol-Brillantblau BB neu may cause sensitisation by skin contact.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Testing for sensitising properties of Remazol-Brillantblau BB neu was performed in female Guinea pigs according to the method of MAGNUSSON & KLIGMAN. Intradermal induction was performed using 5 % Remazol-Brillantblau BB neu in isotonic saline. Dermal induction and challenge treatment were carried out with 25 % Remazol-Brillantblau BB neu in isotonic saline.
Very slight to moderate erythema and very slight edema as well as dry, rough and encrusted skin were observed in the treatment group 24 and 48 hours after removal of the occlusive bandage. No signs of irritation occurred in the control group. The skin surface of all animals was discolored light blue.
Under the conditions of the present study, six of ten animals of the treatment group showed a positive skin response after the challenge procedure.
Based on the results of this study Remazol-Brillantblau BB neu may cause sensitisation by skin contact.
Testing for sensitising properties of Remazol-Brillantblau BB neu Oxifarbstoff was performed in female Guinea pigs according to the method of MAGNUSSON & KLIGMAN. Intradermal induction was performed using 5 % Remazol-Brillantblau BB neu , Oxifarbstoff in isotonic saline. Dermal induction and challenge treatment were carried out with 25 % Remazol-Brillantblau BB neu, Oxifarbstoff in isotonic saline.
The treated animals showed no clinical signs of intoxication throughout the study.
The intradermal inject ions with Freund's Adjuvant (with and without test substance) caused moderate oedema as well as indurated and scabbed skin. The application sites treated with Freund's Adjuvant alone showed additionally moderate erythema. The intradermal injections with the test substance in the vehicle caused very slight up to slight oedema and slight blue discolourations. The intradermal applications of the vehicle caused no signs of irritation. Additionally the application sites treated with the test substance in Freund's Adjuvant showed blue discolourations, therefore erythema eva1uation was not assessable.
Due to these strong irritation reactions of the skin, 10% sodium dodecylsulfate was not applied at day 7.
After the removal of the patch at day 10, erythema and oedema, indurated and scabbed skin as well as necrosis were observed at the sites previously treated with Freund's Adjuvant. The injection sites treated with the test substance in the vehicle and with the vehicle alone showed no signs of irritation. Additionally, blue discoloured skin was noted in the animals of the treatment group.
The body weight gains of the treated animals were not impaired.
After the challenge treatment, no signs of irritation were observed 24 and 48 hours after removal of the occlusive bandage in the control group and in the treated group. The treated skin areas were discoloured slightly blue.
Under the conditions of the present study, none of ten animals of the treatment group showed a positive skin response after the challenge procedure. Based on the results of this study Remazol-Brillantblau BB neu, Oxifarbstoff showed no evidence for sensitizing properties.
Migrated from Short description of key information:
Skin sensitizing effects have been observed with Reactive Blue 220, but not with its degradation product Reactive Blue 220-OH.
Justification for classification or non-classification
Skin sensitizing effects have been observed with Reactive Blue 220, but not with its degradation product Reactive Blue 220-OH.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.